- Conditions
- Multiple Sclerosis, Multiple Sclerosis-Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Interventions
- Acute Intermittent Hypoxia, Sham-Acute Intermittent Hypoxia
- Other
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Interventions
- Glycemic load, Calorie restriction, Behavioral support
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • St Louis, Missouri
- Conditions
- Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
- Interventions
- Metformin 500 Mg Oral Tablet, up to 4 tablets a day, Placebo oral tablet identical to metformin, up to 4 tablets a day
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Remibrutinib, Teriflunomide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,007 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Hanford, California • Los Angeles, California + 42 more
- Conditions
- Multiple Sclerosis
- Interventions
- Ocrelizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Carmichael, California + 52 more
- Conditions
- Multiple Sclerosis
- Interventions
- AZD0120 - Regimen 1, AZD0120 - Regimen 2
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Progressive Multiple Sclerosis
- Interventions
- G-EO System (Reha Technology AG: Olten, Switzerland), Conventional Physical Therapy
- Device · Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Multiple Sclerosis
- Interventions
- ofatumumab with PRF, ofatumumab with AI
- Combination Product
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 13
- States / cities
- Fullerton, California • Aurora, Colorado • Basalt, Colorado + 9 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Interventions
- natalizumab, standard of care
- Drug · Other
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 9 more
- Conditions
- Primary Progressive Multiple Sclerosis
- Interventions
- generation of 'omic markers of disease progression
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 3
- States / cities
- Concord, North Carolina • Durham, North Carolina • Raleigh, North Carolina
- Conditions
- Multiple Sclerosis
- Interventions
- ABT-555, Placebo
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 8
- States / cities
- Orlando, Florida • Lenexa, Kansas • Baltimore, Maryland + 5 more
- Conditions
- Secondary Progressive Multiple Sclerosis (SPMS)
- Interventions
- Remibrutinib (blinded), Placebo, Remibrutinib (Open label)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Multiple Sclerosis (MS) Secondary Progressive
- Interventions
- Dasatinib and quercetin
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Multiple Sclerosis
- Interventions
- LY3541860, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Gulf Breeze, Florida • Winter Park, Florida • Northbrook, Illinois + 3 more
- Conditions
- Migraine, Headache, Multiple Sclerosis, Insomnia
- Interventions
- Smartphone-Based Progressive Muscle Relaxation Therapy (PMR), Monitored Usual Care (MUC)
- Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Sclerosis
- Interventions
- Intrathecal MSC-NP injection, Intrathecal saline injection
- Biological · Other
- Lead sponsor
- Tisch Multiple Sclerosis Research Center of New York
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
- Interventions
- TRX319, Bendamustine
- Biological · Drug
- Lead sponsor
- Tr1X, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas • St Louis, Missouri
- Conditions
- Progressive Multiple Sclerosis
- Interventions
- Light therapy
- Device
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis
- Interventions
- Idebenone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Non-Active Secondary Progressive Multiple Sclerosis, Non-Active SPMS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Autoimmune Diseases, Demyelinating Diseases, Immune System Diseases, Demyelinating Autoimmune Diseases, Central Nervous System (CNS)
- Interventions
- IDP-023, Ocrelizumab, Interleukin-2, Cyclophosphamide, Fludarabine, Mesna
- Drug
- Lead sponsor
- Indapta Therapeutics, INC.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- Stanford, California • Aurora, Colorado • Orlando, Florida + 2 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Remibrutinib, Teriflunomide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fort Smith, Arkansas + 47 more